Health Catalyst (HCAT) Q1 2026 Earnings Transcript

Health Catalyst reported Q1 revenue of $70.8 million and adjusted EBITDA of $9.1 million, both above guidance, but lowered the narrative around 2026 due to migration-related revenue pressure. Full-year guidance calls for $260 million-$265 million in revenue and $30 million-$33 million in adjusted EBITDA, while Project Nexus targets $30 million in annualized cost savings and the company disclosed about $30 million of at-risk ARR still under review. Management is pushing a technology and AI-led mix shift, but near-term professional services margin compression and churn tied to the DOS-to-Ignite migration remain meaningful headwinds.

Analysis

HCAT is trying to re-rate itself from a services-heavy migration story into a software-and-intelligence platform, but the market should focus on the sequencing risk: the company is deliberately accepting a 2026 revenue air pocket to cleanse the customer base and reprice the business model. That makes this less a simple margin expansion story and more a two-stage transition where the first derivative improves before the absolute growth rate does. The key second-order effect is that every retained DOS account now has a higher lifetime value only if Ignite Intelligence becomes the default attach, so bookings quality matters more than headline ARR retention.

Project Nexus is the real valuation lever, not the quarterly beat. A $30M run-rate savings target against a roughly $260M-$265M revenue base is material, but investors should haircut the benefit because restructuring savings arrive unevenly while migration-related gross margin drag persists through the year. The hidden upside is that a leaner org plus AI-assisted engineering could let HCAT ship faster without proportionally more headcount, which is the prerequisite for multiple expansion; the hidden downside is that execution slippage would expose the company to both slower conversion and a weaker services backstop.

The competitive dynamic is shifting away from infrastructure vendors and toward outcome-layer software. Management explicitly framed the data layer as commoditized, which is effectively an admission that the moat must come from proprietary clinical and cost-improvement models; that creates a narrower but potentially stronger franchise if the AI products gain adoption, but it also invites faster commoditization of the lower-value modules. The contrarian read is that the market may be underestimating how much of the 2026 reset is self-inflicted and therefore reversible, but also overestimating how quickly clients will re-commit after being pushed through a painful migration cycle.

Key Decisions for Investors

• HCAT: avoid chasing the post-call pop; wait 1-2 quarters for evidence that bookings convert into revenue inside the promised 3-6 month window before considering a long. Better entry is on a pullback if Q2 shows margin discipline and bookings acceleration.
• HCAT: for catalyst-driven traders, consider a limited-risk call spread into the next two earnings prints only if management proves 2026 revenue trough is stabilizing. Risk/reward is attractive only if the market starts capitalizing the $30M cost-savings narrative.
• HCAT vs SNOW pair: long HCAT / short SNOW only if you want a niche healthcare vertical AI story over horizontal infrastructure. The thesis is that HCAT’s proprietary improvement data is more defensible than generic data plumbing, but this pair is high risk and requires proof of attach rates.
• If long HCAT, hedge with a small short or put spread position into Q2-Q3 in case migration churn re-accelerates. The main tail risk is that the retained $22M estimate proves too optimistic and forces another reset.
• Watch for a re-entry trigger above a sustained $10-$12 cash/EBITDA multiple only after the market sees evidence that the services mix is shrinking without impairing software ARR quality.